The Future of Bispecific Antibodies with Dr. Philippe Moreau

Bispecific antibodies are a growing class of treatment in multiple myeloma. Learn from global expert and International Myeloma Society (IMS) President Dr. Philippe Moreau about the advances being made in bispecific antibodies and what clinicians are learning about how and when to best use this therapy. Dr. Moreau will provide a review of approved and in-development bispecific antibodies, side effect management and more. Learn how HealthTree and IMS are partnering on the HealthTree Bispecific Antibody Study to provide more data and patient experiences to help the research community come to faster conclusions about this new, exciting treatment.